Science-led biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Monday that Ultomiris, a long-acting C5 complement inhibitor, has gained FDA approval for treating adults with anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD), offering relapse-free potential.
The CHAMPION-NMOSD Phase III trial demonstrates significant relapse risk reduction.
NMOSD, a rare autoimmune disease affecting the central nervous system, sees a diagnosed prevalence of around 6,000 adults in the US. Ultomiris's safety profile remains consistent, with no new adverse events observed.
Ultomiris, already approved in Japan and the EU for NMOSD, inhibits the complement cascade to prevent attacks on healthy cells.
AstraZeneca's rare disease-focused Alexion group leads the development of Ultomiris, aiming to serve patients with rare and devastating conditions globally.
Lipocine doses first cohort in LPCN 1154 study
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
AstraZeneca announces US approval for Ultomiris for NMOSD treatment
GenSight Biologics declares efficacy and safety of LUMEVOQ four years post-injection
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials